Study of drug combo for anaplastic thyroid cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two medications—zanzalintinib (a targeted drug that may stop cancer cells from growing) and cemiplimab (an immunotherapy that helps your immune system fight cancer)—for people with anaplastic thyroid cancer, a rare and aggressive type. The goal is to see if this combo helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have anaplastic thyroid cancer (a rare and fast-growing type) that cannot be removed with surgery or has spread. In some cases, if you have a specific gene change (BRAF mutation) and can't take the standard drugs, you may still qualify.
- You need to be in generally good health, able to do light activities, and have adequate blood, liver, and kidney function.
- You cannot have had previous treatment with certain drugs, including immunotherapy (like cemiplimab) or certain targeted therapies (like lenvatinib or cabozantinib).
- You cannot have certain medical conditions, like unstable heart problems, uncontrolled infections, or recent major bleeding issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, XL092 and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer. The drugs aim to shrink tumors before surgery and help the immune system fight the cancer.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This trial tests two oral medications, avutometinib and defactinib, for people with advanced thyroid cancer that has specific genetic changes. The goal is to see if these drugs can shrink tumors or slow their growth.
This trial tests a new three-drug combination for advanced head and neck cancer that cannot be cured by local treatments. It aims to find the best dose of a targeted therapy called Zanzalintinib when given with two standard immunotherapy and targeted drugs.
Hear when a new Anaplastic Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.